.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Queensland Health
Chinese Patent Office
QuintilesIMS
UBS
Moodys
Healthtrust
Merck
Harvard Business School
Federal Trade Commission

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022210

« Back to Dashboard
NDA 022210 describes ZENPEP, which is a drug marketed by Forest Labs Inc and is included in one NDA. It is available from four suppliers. There are seven patents protecting this drug. Additional details are available on the ZENPEP profile page.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Summary for NDA: 022210

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:7

Suppliers and Packaging for NDA: 022210

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL 022210 NDA Allergan, Inc. 0023-6112 0023-6112-01 1 BOTTLE, GLASS in 1 CARTON (0023-6112-01) > 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE, GLASS
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL 022210 NDA AUTHORIZED GENERIC X-GEN Pharmaceuticals, Inc. 39822-0205 39822-0205-1 1 BOTTLE in 1 CARTON (39822-0205-1) > 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrength27,000USP UNITS;5,000USP UNITS;17,000USP UNITS
Approval Date:Aug 27, 2009TE:RLD:Yes
Patent:► SubscribePatent Expiration:Feb 20, 2028Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Feb 20, 2028Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Feb 20, 2028Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Express Scripts
Citi
Johnson and Johnson
Novartis
UBS
Boehringer Ingelheim
Chinese Patent Office
Moodys
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot